Keywords: belgium, ucb, beats, expectations, rise, first-half, net
Belgium's UCB beats expectations with 34% rise in first-half net profits
Article | 09 August 2004
Belgian pharmaceutical and chemicals firm UCB, which has just completedits acquisition of the UK's largest biotechnology company Celltech (Marketletter May 24), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
